From Photon to Circadian Clock: Tracing Light's Signalling Journey Through the Retina

A Signal Arrives at Speed

Of all the signals the human body receives, light is arguably the most consequential. It arrives at roughly 300,000 kilometres per second, carries no chemical identity, and yet determines how we see, when we sleep and — for a significant minority of the population — how we feel through the dark months of a British winter. The story of how a photon becomes biology is, at its heart, a story of signalling cascades.

Phototransduction: The Retina's Molecular Amplifier

The journey begins in the photoreceptor cells of the retina — rods and cones — where a photon is absorbed by a pigment molecule called retinal, bound to a G protein-coupled receptor known as opsin. In rods, this receptor is rhodopsin; in cones, variants of opsin tuned to different wavelengths give us colour vision.

Absorption of a single photon changes the shape of retinal, activating rhodopsin and setting off a cascade with extraordinary amplification. Activated rhodopsin stimulates transducin, a G protein, which in turn activates an enzyme called phosphodiesterase. This enzyme breaks down cyclic GMP, causing ion channels in the photoreceptor membrane to close and the cell to hyperpolarise. Counterintuitively, light switches photoreceptors off, and it is this reduction in neurotransmitter release that downstream cells interpret as illumination.

The pharmacological relevance is immediate. Beta-blockers used to treat glaucoma act on receptors within this signalling environment, and a family of drugs targeting the visual cycle — including treatments for certain inherited retinal degenerations — depends on a detailed understanding of phototransduction's biochemistry.

The Third Photoreceptor: Light for the Clock, Not the Eye

For much of the twentieth century, it was assumed all retinal light detection served vision. We now know otherwise. A small population of retinal ganglion cells — around one per cent of the total — contains a pigment called melanopsin and is directly photosensitive. These intrinsically photosensitive retinal ganglion cells (ipRGCs) are particularly responsive to blue wavelengths around 480 nanometres.

Crucially, these cells do not project to the visual cortex. Their principal target is the suprachiasmatic nucleus (SCN) of the hypothalamus — the master circadian pacemaker. Light entering through this pathway does not produce an image; it produces a timestamp, synchronising the body's internal 24-hour clock with the external day.

From the SCN, signalling travels to the pineal gland, which secretes melatonin — the hormone of darkness. Light suppresses melatonin release; darkness permits it. The rise of melatonin in the evening is, in effect, the body's chemical instruction to prepare for sleep.

Dark Decembers and Seasonal Affective Disorder

This signalling architecture acquires particular significance in the UK, where winter daylight can last barely eight hours in northern cities such as Aberdeen or Manchester. Reduced morning light exposure delays circadian synchronisation and prolongs melatonin secretion into the waking day — a state associated with the low mood, lethargy and carbohydrate craving characteristic of seasonal affective disorder (SAD).

The pharmacological response follows directly from the signalling biology. Bright light therapy boxes, delivering light at intensities far exceeding typical indoor illumination, act as an exogenous signal to the SCN, suppressing melatonin and reinforcing circadian timing. Randomised trials support their use in SAD, with morning administration generally proving most effective — consistent with the timing sensitivity of the circadian system.

Melatonin itself, and the newer melatonin receptor agonists such as ramelteon, represent the converse approach: supplementing or mimicking the darkness signal where circadian timing has failed. In the UK, melatonin is available on prescription for certain sleep disorders, and its rational use depends on understanding exactly where in the signalling chain the problem lies.

One Signal, Many Outputs

What emerges from this account is the economy of biological design. A single class of signals — photons — is decoded by distinct receptor systems within the same retina to produce radically different outputs: vision through rhodopsin and the cone opsins, and timekeeping through melanopsin and the SCN. That pharmacology can intervene at each stage, from the photoreceptor to the pineal gland, reflects how thoroughly the signalling logic has been deciphered. For students of cell signalling, the visual system offers perhaps the clearest demonstration that understanding a pathway is the prerequisite for treating its failures.